Adenocarcinoma of the lung, a leading cause of cancer death, frequently displays mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing mutated EGFR, ROS1, or ALK, there is no pathway-targeted therapy for patients with KRAS-mutated lung cancer. In preclinical models, expression of oncogenic KRAS G12D in the lung epithelium of adult mice initiates development of lung adenocarcinoma through activation of downstream signaling pathways. In contrast, mutationally activated BRAF V600E , a KRAS effector, fails to initiate lung carcinogenesis despite highly efficient induction of benign lung tumorigenesis. To test if phosphoinositide 3-kinase (PI3K)-a (PIK3CA), another KRAS effector, might cooperate with oncogenic BRAF V600E to promote lung cancer progression, we used mice carrying a conditional allele of Pik3ca that allows conversion of the wild-type catalytic subunit of PIK3CA to mutationally activated PIK3CA H1047R . Although expression of PIK3CA H1047R in the lung epithelium, either alone or in combination with PTEN silencing, was without phenotype, concomitant expression of BRAF V600E and PIK3CA H1047R led to dramatically decreased tumor latency and increased tumor burden compared with BRAF V600E alone. Most notably, coexpression of BRAF V600E and PIK3CA H1047R elicited lung adenocarcinomas in a manner reminiscent of the effects of KRAS G12D . These data emphasize a role for PI3K signaling, not in lung tumor initiation per se, but in both the rate of tumor growth and the propensity of benign lung tumors to progress to a malignant phenotype. Finally, biologic and biochemical analysis of BRAF V600E /PIK3CA H1047R -expressing mouse lung cancer cells revealed mechanistic clues about cooperative regulation of the cell-division cycle and apoptosis by these oncogenes. Cancer Res; 73(21); 1-14. Ó2013 AACR.
Introduction
Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related mortality (1) . Recently identified mutations in proto-oncogenes in NSCLC have provided strategies for the deployment of pathway-targeted therapies (2) . However, despite the success of such agents in the treatment of genetically defined subsets of lung cancer, most patients with NSCLC do not have recourse to the use of such agents.
Of the proto-oncogenes mutated in NSCLC, KRAS remains the most common (!25%) and the most pharmacologically intractable (2) . Consequently, attention has turned to inhibiting key downstream signaling pathways required for maintenance of KRAS-mutated NSCLC. Moreover, KRAS effectors such as BRAF, phosphoinositide 3-kinase (PI3K), and AKT are directly implicated as bona fide human lung cancer genes (2) (3) (4) (5) . However, a key outstanding question is, what KRAS G12D regulated pathways are essential for lung carcinogenesis in GEM models? Although KRAS G12D -driven tumors are MAP-ERK kinase 1/2 (MEK1/2) dependent, expression of BRAF V600E in the lung epithelium elicits benign lung tumors that rarely progress to malignancy due to a senescence-like growth arrest (6) (7) (8) . In contrast, although transgenic expression of mutationally activated PIK3CA H1047R in the lung epithelium was reported to promote lung tumorigenesis, combined inhibition of PI3K/mTorc had no effect on established KRAS G12D -initiated lung tumors (9) . Consequently, we tested whether mutationally activated BRAF V600E and PIK3CA H1047R might cooperate in promoting lung carcinogenesis using GEM models (6, 10) .
Perhaps surprisingly, we could not substantiate reports that PIK3CA H1047R can initiate lung tumorigenesis. However, concomitant expression of both BRAF V600E and PIK3CA H1047R led to rapid onset of lung tumorigenesis with evidence of malignant progression observed 6 months after tumor initiation. The cooperative effects of PIK3CA H1047R in vivo were AKT dependent, and were modeled in vitro. Finally, we show that both BRAF V600E and PIK3CA signaling is necessary for proliferation and survival of BRAF V600E /PIK3CA H1047R -expressing lung cancer cells, and show that these pathways cooperatively regulate the cell-division cycle and apoptosis.
Materials and Methods

Mice and adenovirus delivery
Animal experiments were carried out in accordance with protocols approved by the University of California, San Francisco (San Francisco, CA) Institutional Animal Care and Use Committee (IACUC). BRaf CA (Braf tm1Mmcm ), Trp53 lox (Trp53 tm1Brn ), PIK3CA lat-H1047R , and Pten lox mice were bred and genotyped as previously described (6, (10) (11) (12) (13) . All mice were back-crossed onto the FVB/NJ genetic background for at least 10 generations. Experiments were carried out using littermates as controls whenever possible. Stocks of adenovirus-encoding Cre recombinase were purchased from Viraquest or the University of Iowa, Gene Transfer Vector Core (14) . Adenoviruses with cell-specific expression of Cre recombinase were generously provided by Kate Sutherland and Anton Berns (NKI, Amsterdam) and purchased from the University of Iowa, Gene Transfer Vector Core (14) . Intranasal instillation of adenovirus for infection of the mouse lung epithelium was carried out as previously described (15) . Tumor-bearing mice were euthanized for analysis either at a predetermined time point or when their body conditioning score (BCS) was 2 or less (16) .
Histology and quantification of lung tumor burden
Lungs were removed, fixed in zinc-buffered formalin (ZBS), and stored in 70% (v/v) ethanol before paraffin embedding. Then, 6 mm sections were stained with hematoxylin and eosin (H&E) on slides, and scanned with an Aperio Scan-Scope scanner. Quantification of tumor number, size, and overall burden of individual lung sections was conducted using Aperio Spectrum ImageScope software. Overall tumor burden was calculated as (area of lung section occupied by tumor)/(total area of section) in micron per square meter.
Treatment of mice with pathway-targeted therapeutics PD325901 (Hansun Trading Co.) was formulated in 0.5% (w/v) hydroxy-propyl-methylcellulose (HPMT; Sigma) and administered every day by oral gavage (orally) at a dose of 12.5 mg/kg. MK-2206 (Merck) was formulated in 30% (w/v) Captisol (Ligand Technology) and dosed orally at 120 mg/kg every day.
LGX-818 and BKM-120 (Novartis) were formulated in 0.5% carboxymethylcellulose (Sigma) plus 0.5% Tween 80 (Sigma) and dosed orally every day at doses of 30 and 60 mg/kg, respectively. Mice were dosed with drug for predetermined time points or until their BCS was 2 or less, at which point they were euthanized for analysis (16) .
Immunostaining of mouse lung tissue and immunoblotting
ZBS-fixed sections of mouse lungs were subject to citratemediated antigen retrieval and then probed with anti-pS473-AKT, anti-vimentin, anti-PTEN (Cell Signaling Technology), anti-NKX2.1, anti-Ki67, anti-SP-C, and anti-p63 (Santa Cruz Biotechnology). Immunoblotting was done on 50 mg of extracted protein and probed with antisera against various phospho-or backbone-specific antisera as described. Immunoblots were quantified using an Odyssey FC system and Image Studio software.
Lung tumor cell isolation, culture, and analysis
Single-cell suspensions were generated from BRAF V600E / TP53 Null -or BRAF V600E /PIK3CA H1047R /TP53 Null -induced lung cancers and cultured in Hams-F12/Glutamax media with 10% (v/v) FBS. Following outgrowth, single cell-derived clones were isolated. Recombination of BRaf CA , Trp53 lox , and Pik3ca lat alleles was verified by PCR (10) . Expression of oncogenic BRAF V600E was determined by immunoblotting with a mAb (VE1) specific to BRAF V600E (17) .
Cell proliferation was assessed in triplicate cultures of cells treated for 72 hours with dimethyl sulfoxide (DMSO) control, MEK1/2 inhibitor (PD325901; 15.6 nmol/L to 1 mmol/L), extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor (SCH772984; 7.8 nmol/L to 5 mmol/L), AKT1-3 inhibitor (MK-2206; 80 nmol/L to 5 mmol/L), or class 1 PI3K inhibitor (GDC-0941; 80 nmol/L to 5 mmol/L) alone or in combination as indicated using a CellTiter-Glo assay (Promega). Cell-cycle status was assessed in fixed floating and adherent cells stained with anti-bromodeoxyuridine (BrdUrd)-fluorescein isothiocyanate (FITC; Becton-Dickinson) and propidium iodide (Sigma). Sorting of mCherry encoding ecotropic retroviruses was carried out using a FACSCalibur system (Becton Dickinson; refs. 18, 19) . Anchorage-independent colony formation was done by plating 5 Â 10 3 cells in 1.4% (w/v) Sea-Plaque lowmelting temperature agarose (Cambrex) and culturing them for 3 weeks, at which time colony formation was enumerated using a dissecting microscope.
Reverse phase protein array analysis
Reverse phase protein array (RPPA) analysis (Functional Proteomics Core Facility at MD Anderson Cancer Center, Houston, TX) was conducted as previously described (20, 21) and detailed in the Supplementary Data.
Results
Expression of PIK3CA H1047R combined with PTEN silencing fails to induce lung tumors in mice
To test whether PIK3CA H1047R could initiate lung tumorigenesis, we used Pik3ca lat-H1047R mice (Pik3ca lat ) carrying a modified Pik3ca allele that expresses normal PIK3CA before Cre-mediated recombination, after which PIK3CA H1047R is expressed under control of the gene's chromosomal regulatory elements (9, 10) . Cre-mediated genetic alterations were initiated using an adenovirus encoding Cre recombinase (Ad-Cre; ref. 6 ). Because expression of PIK3CA H1047R from a single allele might be insufficient for lung tumorigenesis, we generated mice with every possible heterozygous or homozygous combination of Pik3ca lat in combination with a conditional null allele of Pten (Pten lox ; ref. 11).
The lungs of adult mice of the various Pik3ca lat /Pten lox genotypes were infected with Ad-Cre and euthanized for analysis 3, 6, or 12 months or later postinfection. As a control for successful tumor induction, BRAF V600E expression was initiated in the lung epithelium of BRaf CA mice, which developed benign lung adenomas at high multiplicity requiring euthanasia approximately 12 weeks postinitiation ( Fig. 1A, right ). In contrast, we failed to detect lung tumors in mice carrying conditional alleles of Pik3ca or Pten, either alone or in combination, at 3 or 6 months after Ad-Cre infection (Fig. 1A , left and middle). That PTEN silencing was insufficient for lung tumorigenesis was consistent with previous observations, but the lack of lung tumorigenesis in the compound Pik3ca lat /Pten lox mice was surprising (22) . At 12 months or more, we detected benign adenomas in Pik3ca lat/lat ; Pten lox/lox mice; however, these were rare (< one tumor per mouse). Most of these tumors stained positive for PTEN expression and negative for phospho (p)-AKT, suggesting that they may be spontaneously arising lung tumors unrelated to mouse genotype. However, we also detected very rare lung tumors in Pik3ca lat/lat ; Pten lox/lox mice that stained brightly for pAKT and may, therefore, be due to this combination of genetic modifications (Fig. 1T ). Immunofluorescence analysis of Ad-Cre infected Pik3ca lat or Pik3ca lat/lat mice failed to detect evidence of cells with pAKT or Ki67 expression above that detected in normal mouse lung ( Fig.  1F -M). However, in Pik3ca lat mice carrying either one or two Pten lox alleles, small numbers of airway epithelial hyperplasias were detected ( Fig. 1N -U). Most prevalent in Pik3ca lat/lat ; Pten lox/lox mice, these lesions comprised small numbers of cells that stained negative for PTEN and positive for pAKT, with the strongest pAKT signal detected in lesions in Pik3ca lat/lat ; Pten lox/lox mice (Fig. 1R ). These lesions were 50 mm or less in diameter and not proliferative ( Figure 1 . PI3K pathway activation is insufficient to initiate tumorigenesis in the mouse lung. A, lungs of mice of the indicated genotypes were infected with Ad-Cre and monitored for 3 or 12 months or more as indicated, at which time they were euthanized and their lungs processed for H&E staining. Representative H&E-stained tissue sections from Pik3ca lat/lat (left) or Pik3ca lat/lat ; Pten lox/lox (middle) animals euthanized 6 months after infection. BRaf CA mice analyzed 12 weeks following Ad-Cre initiation are presented as a positive control (right). B-U, mouse lung sections from control (uninfected) or mice of the indicated genotypes treated as described in A were stained with 4 0 , 6-diamidino-2-phenylindole (DAPI), antisera against phospho-(p)-AKT, or Ki67 as indicated. Insets indicate higher magnification of regions of airway hyperplasia.
to the effects of KRAS G12D or BRAF V600E , there was no combination of Pik3ca lat and Pten lox that elicited lung tumors in mice within 6 months after Ad-Cre (6, 9, 12) .
PIK3CA H1047R dramatically accelerates BRAF V600E -driven lung tumorigenesis
To determine if PIK3CA H1047R cooperates with BRAF V600E in lung tumorigenesis, we infected adult BRaf CA or compound BRaf CA ; Pik3ca lat mice with either 5 Â 10 6 or 10 7 pfu Ad-Cre. Kaplan-Meier survival analysis of mice infected with 5 Â 10 6 pfu Ad-Cre indicated that all BRaf CA ; Pik3ca lat mice reached end-stage by approximately 50 days based on their BCS, a time at which all BRaf CA mice remained healthy ( Fig. 2A ; ref. 16 ). Taken together, BRaf CA mice lived twice as long as BRaf CA ; Pik3ca lat littermates after initiation (median survival, 100 vs. 39 days, P ¼ 1.25 Â 10 À5 ; Fig. 2B ). Furthermore, 3 weeks after infection with 10 7 pfu Ad-Cre, many BRaf CA ; Pik3ca lat mice displayed labored breathing and reduced body weight, indicating onset of lethal lung tumorigenesis, at which time representative mice were euthanized for necropsy ( Fig. 2B ). Compared with control BRaf CA mice, BRaf CA ; Pik3ca lat mice presented with more tumors (96 vs. 54, P ¼ 0.025) and Pik3ca lat mice were infected with 10 7 pfu Ad-Cre to initiate expression of BRAF V600E either alone or in combination with PIK3CA H1047R . Mice were euthanized 3 weeks later with lungs processed for H&E staining. Scale bar, 100 mm. C, tumor number, size, and burden were calculated as described in Materials and Methods in mice carrying either BRAF V600E or BRAF V600E / PIK3CA H1047R -expressing tumors.
BRAF V600E /PIK3CA H1047R -expressing tumors were larger than their BRAF V600E -expressing counterparts (52,516 vs. 6,782.5 mm 2 , P ¼ 0.004; Fig. 2B and C). Three weeks postinitiation, BRAF V600E /PIK3CA H1047R -expressing lung lesions manifested as large adenomas, whereas BRaf CA mice displayed only alveolar and/or airway hyperplasias ( Fig. 2B and C) . Taken together, BRaf CA ; Pik3ca lat mice displayed a 14-fold higher tumor burden at 3 weeks postinitiation compared with BRaf CA mice (16.8% vs. 1.2%, P ¼ 0.01; Fig. 2C ).
PTEN silencing enhances BRAF V600E -induced lung tumorigenesis
To complement analysis of the effects of PIK3CA H1047R on BRAF V600E -induced lung tumorigenesis, we tested if deregulation of PI3K signaling through PTEN silencing might have similar effects. Indeed, this is a combination of alterations commonly found in human melanoma and that cooperate in GEM models of the disease (5, 23) . We infected BRaf CA , BRaf CA ; Pik3ca lat/þ , or compound BRaf CA ; Pten lox/lox with 10 6 pfu Ad-Cre with mice euthanized 4 weeks after initiation. Compared with control BRaf CA mice, BRaf CA ; Pik3ca lat and BRaf CA/þ ; Pten lox/lox mice displayed a 10-fold or more and a 4-fold increase in overall tumor burden, respectively (2.8% vs. 31.2% vs. 10.8%, Fig. 3A and B ). Although most lung tumor cells arising in BRaf CA mice displayed readily detectable PTEN expression, the vast majority of tumor cells in BRaf CA ; Pten lox/lox mice were PTEN negative ( Fig. 3C ). These data indicate that the statistically significant difference between lung tumorigenesis in BRaf CA ; Pik3ca lat vs. BRaf CA/þ ; Pten lox/lox mice is not due to inefficient PTEN silencing. Taken together, these data support the hypothesis that activation of PI3K signaling, either by coexpression of PIK3CA H1047R or PTEN silencing, cooperates with BRAF V600E in lung tumorigenesis (22) .
Pharmacologic blockade of MEK or AKT prevents the growth of BRAF V600E /PIK3CA H1047R lung tumors
To assess the role of downstream signaling components on the cooperation between BRAF V600E and PIK3CA H1047R , we used pharmacologic inhibitors of either MEK1/2 (PD325901) -initiated lung tumorigenesis. A, mice of the indicated genotypes were infected Ad-Cre and euthanized 4 weeks later for analysis of tumor burden, which was quantified as described previously. Scale bar, 100 mm. B, lung tumors arising in BRaf CA or BRaf CA ; Pten lox/lox mice were stained with antisera against PTEN. 24, 25) . These agents are nonsubstrate competitive, allosteric inhibitors with high specificity and selectivity. BRaf CA or BRaf CA ; Pik3ca lat mice were infected with 10 6 Ad-Cre and then separated into two groups for treatment with either vehicle control or MK-2206 (120 mg/kg, every day, orally) to inhibit AKT for an additional 4 to 5 weeks, at which time mice were euthanized.
MK-2206 treatment had no effect on BRAF V600E -initiated lung tumor burden (vehicle, 25% vs. MK-2206, 22%, P ¼ 0.63; Supplementary Fig. S1A ). In contrast, consistent with previous results, MEK1/2 inhibition largely abolished BRAF V600E -induced lung tumorigenesis (not shown; refs. 6, 7). These data strongly suggest that BRAF V600E -induced lung tumors are AKT independent for their initial growth.
In contrast to BRAF V600E -driven tumors, MK-2206 had a significant effect on BRAF V600E /PIK3CA H1047R -driven lung tumorigenesis ( Fig. 4A and B ). Although 4 weeks of MK-2206 dosing had no effect on overall tumor number (vehicle, 31.8 vs. MK-2206, 28.7; P ¼ 0.76), both tumor size (vehicle, 121,413 mm 2 vs. MK-2206, 30,083 mm 2 ; P ¼ < 0.0001) and overall tumor burden (vehicle, 20.7%; MK-2206, 5%; P ¼ 0.004) were significantly reduced following AKT inhibition ( Fig. 4B ). Indeed, tumor sizes and overall tumor burden that developed in BRaf CA ; Pik3ca lat mice in the presence of MK-2206 were roughly equivalent to that observed in BRaf CA mice. These data support the hypothesis that AKT activity is required for the cooperation between BRAF V600E and PIK3CA H1047R in lung tumorigenesis but largely dispensable for the growth of BRAF V600E -induced lung tumors. Inhibition of pS473-AKT by MK-2206 was confirmed by immunoblot analysis of lysates of BRAF V600E or BRAF V600E /PIK3CA H1047R -expressing lung tumors treated with either vehicle or MK-2206 2 hours before euthanasia ( Supplementary Fig. S1B and S1C, respectively).
Previous studies have indicated the exquisite sensitivity of BRAF V600E -driven lung tumors to MEK1/2 inhibition with PD325901 (6, 7). However, analysis of lung, pancreas, and colon cancer cell lines suggests that PI3K signaling, either by mutation of PIK3CA or PTEN silencing, can render cells less sensitive to MEK inhibition possibly by sustaining the expression of Dtype cyclins (26, 27) . Therefore, we sought to determine if BRAF V600E /PIK3CA H1047R lung tumors remained sensitive to MEK1/2 inhibition in vivo. Lung tumors were initiated in BRaf CA ; Pik3ca lat mice, and 2 weeks later mice were dosed with vehicle or PD325901 (12.5 mg/kg, every day, orally) for a further 4 weeks, at which time mice were euthanized ( Fig. 4A  and B ). Compared with controls, MEK1/2 inhibitor-treated mice displayed a 15-fold reduction in tumor number (31.8 vs. 2.0, P ¼ 0.005). Lesions detected in PD325901-treated BRaf CA ; Pik3ca lat mice were largely small alveolar or airway hyperplasias, and no fully formed adenomas were present in these mice. This resulted in an approximately 12-fold reduction in average tumor size (vehicle, 121,413 mm 2 vs. PD325901, 10,914 mm 2 for drug-treated mice, P < 0.0001) and a more than 20,000-fold reduction in overall tumor burden (vehicle, 20.7% vs. PD325901, 0.001%, P ¼ 0.0004) compared with controls ( Fig.  4B ). Consequently, these data indicate that BRAF V600E /PIK3-CA H1047R lung tumors remain sensitive to the antitumor effects of MEK1/2 inhibition and highlight the central importance of BRAF V600E !MEK!ERK signaling in the growth of BRAF V600E / PIK3CA H1047R -induced lung tumors.
Enhanced therapeutic benefit of combined BRAF V600E plus PIK3CA H1047R inhibition against BRAF V600E / PIK3CA H1047R -expressing lung tumors
To examine the requirement for sustained signaling in maintenance of BRAF V600E /PIK3CA H1047R -expressing lung tumors, we initiated tumorigenesis in 34 BRaf CA ; Pik3ca lat mice and monitored them for 5 weeks until they were close to endstage. At this time, two mice were euthanized with the remaining mice divided into four cohorts for the following interventions: (i) no treatment; (ii) class 1 PI3K inhibitor (BKM-120, 60 mg/kg, every day, orally); (iii) BRAF V600E inhibitor (LGX-818, 30 mg/kg, every day, orally); or (iv) combination of BKM-120 and LGX-818 (60 and 30 mg/kg, respectively, every day, orally; refs. 28, 29) . Drug benefit was assessed by Kaplan-Meier analysis with mice euthanized when their BCS was 2 or less ( Fig. 4C ; ref. 16 ). In addition, we monitored mouse body weight, which correlates with changes in tumor burden ( Fig. 4D ).
There was no statistical difference in survival between untreated (n ¼ 6) or BKM-120-treated (n ¼ 8) mice, all of which lost weight requiring euthanasia within 5 days after dosing ( Fig. 4C and D) . In contrast, mice treated with LGX-818 (n ¼ 8) or combined LGX-818 plus BKM-120 (n ¼ 8) displayed increased survival ( Fig. 4C ) such that no mice in the combination arm required euthanasia. Although LGX-818-treated mice continued to lose weight, this was at reduced rate and only one-eighth mice developed end-stage disease. Finally, mice treated with combined LGX-818 plus BKM-120 displayed immediate signs of improvement in their BCS that continued throughout the treatment period ( Fig. 4D ).
Analysis of mouse lungs from each group indicated that untreated and BKM-120-treated mice displayed a substantial tumor burden (average of $28% and 23%) with no difference between them, consistent with the lack of benefit afforded by BKM-120 ( Fig. 4E and F) . In contrast, LGX-818-treated mice displayed reduced tumor burden ($10%) compared with control or BKM-120-treated mice. The therapeutic benefit of LGX-818-treated mice was further enhanced by combination with BKM-120 ($3% tumor burden) consistent with the survival and health benefits afforded these mice. Taken together, combined blockade of BRAF V600E and PIK3CA H1047R signaling in BRAF V600E /PIK3CA H1047R -expressing lung tumors was superior to blockade of BRAF V600E or PIK3CA H1047R alone.
PIK3CA H1047R promotes malignant progression of BRAF V600E -induced tumors
KRAS G12D -induced lung tumorigenesis in GEM models depends on RAF!MEK!ERK, PI3K, RAC1 and NF-kB signaling (7, 9, (30) (31) (32) (33) . However, to date, activation of single nodes downstream of KRAS.GTP fails to recapitulate the malignant progression displayed by KRAS G12D -initiated lung tumors. Although BRAF V600E induces benign lung tumors, such lesions are low grade and fail to progress to lung cancer (6, 7) . As shown here, although PIK3CA H1047R is unable to initiate lung tumorigenesis, it promotes the growth BRAF V600E -initiated lung tumors. This prompted us to evaluate whether BRAF V600E and PIK3CA H1047R might cooperate for malignant lung cancer progression. To that end, tumors were initiated in either BRaf CA or BRaf CA ; Pik3ca lat mice (5 Â 10 5 pfu Ad-Cre) with mice euthanized 25 weeks later for evaluation (7, 34) .
In contrast with early time points, overall tumor number was not different between BRaf CA and BRaf CA ; Pik3ca lat mice with an average of 30 tumors per lobe recorded in both genotypes ( Fig. 5A and B ). However, individual lung tumors in BRaf CA ; Pik3ca lat mice were larger than those in BRaf CA mice (35,000 vs. 5,000 mm 2 ; P ¼ 0.0005; Fig. 5B ). Differences in tumor size were reflected by overall increased tumor burden in BRaf CA ; Pik3ca lat mice (24% vs. 6%; P ¼ 0.0001; Fig. 5B ). These data suggest that PIK3CA H1047R does not influence the / PIK3CA H1047R tumors. A, BRAF V600E or BRAF V600E / PIK3CA H1047R -expressing lung tumors were initiated in mice of the appropriate genotype using Ad-Cre. Two weeks later, mice were dosed for a further 4 weeks with vehicle control, MK-2206, or PD325901 as described in Materials and Methods, at which time mice were euthanized and lungs prepared for H&E staining. Scale bar, 500 mm. B, the effects of MK-2206 or PD325901 on lung tumor number, size, and overall burden in mice bearing BRAF V600E or BRAF V600E /PIK3CA H1047Rexpressing lung tumors were estimated as described in Materials and Methods. ÃÃ , P 0.005. C and D, lung tumors were initiated in BRaf CA ; Pik3ca lat mice and, 5 weeks later, they were either untreated or treated with inhibitors of BRAF V600E (LGX-818) or class 1 PI3Ks (BKM-120) either alone or in combination as indicated. Mice were euthanized when they developed end-stage disease, and this was used to calculate a Kaplan-Meier survival curve (C). In addition, the weight of every mouse in each group was measured and normalized to its starting weight, which was set at 100%, and the average normalized weight of all mice in a treatment group was used to assess their response to treatment (D). E and F, lung tumor burden in BRaf CA ; Pik3ca lat treated as described in C and D was assessed by H&E staining of lung tumor sections. Lung tumor specimens from untreated or BKM-120-treated mice came from mice with endstage disease, whereas the specimens from the LGX-818 or combined LGX-818 plus BKM-120 treatments were derived from mice at the end of the 4-week dosing schedule. ÃÃÃ , P ¼ 0.0003; ÃÃÃÃ , P < 0.0001. frequency of BRAF V600E -initiated cells in the lung epithelium, but decreases the latency period before tumorigenesis and also increases their overall proliferative potential.
One possible explanation for the larger tumors observed in BRaf CA ; Pik3ca lat mice is that each tumor arises in a polyclonal manner from more than one initiated cell. To test the clonality of BRAF V600E /PIK3CA H1047R lung tumors, we generated BRaf CA ; Pik3ca lat mice containing the "Confetti" reporter (Gt(ROSA) 26Sor tm1(CAG-Brainbow2.1)Cle , R26 Confetti hereafter; Supplementary  Fig. S2; ref. 35 ). The action of Cre on the R26 Confetti reporter elicits a recombination event that stochastically places one of four different fluorescent proteins (FP) downstream of the CAG promoter. Therefore, if BRAF V600E /PIK3CA H1047R -induced lung tumors are clonally derived, each tumor should express a single FP. However, if tumors are polyclonal in origin, they will contain a mixture of cells with different FP expression. BRaf CA ; Pik3ca lat ; R26 Confetti mice were infected with 10 7 pfu Ad-Cre, with lung tumors analyzed 9 weeks later. Individual BRAF V600E /PIK3CA H1047R lung tumors were uniformly positive for a single FP, indicating that each tumor is clonally derived from a single initiated cell ( Supplementary Fig. S2 ).
To assess malignant progression, we used a grading scheme based on the classification of lung lesions in GEM models to assess the grade of more than 250 tumors from mice of each Figure 5 . PIK3CA H1047R promotes malignant progression of BRAF V600E -initiated lung tumors. A, BRAF V600E or BRAF V600E / PIK3CA H1047R -expressing lung tumors were initiated in mice of the appropriate genotype using Ad-Cre with mice monitored for 25 weeks, at which time they were euthanized and their lungs processed for H&E staining. Scale bar, 50 mm. Lung tumor number, size, and overall burden were assessed as described in Materials and Methods. B, the grade of BRAF V600E or BRAF V600E / PIK3CA H1047R -expressing lung tumors was assessed on a 4-point scale using the grading criteria described in Supplementary  Fig. S3 Fig. 5C and Supplementary Fig. S3A and S3B ; refs. 12, 34). Hyperplasia was designated grade 1, benign adenomas as grade 2, larger adenomas as grade 3, and adenosquamous or adenocarcinomas as grade 4. BRAF V600E -induced lung lesions were predominantly grade 1 or 2 with rare examples of grade 3 detected. In contrast, BRAF V600E / PIK3CA H1047R -induced lesions were generally grade 2 or 3 adenomas but approximately 3% of tumors were malignant grade 4 adenosquamous or adenocarcinoma lesions. These data indicate that BRAF V600E cooperates with PIK3CA H1047R to both accelerate early-stage lung tumorigenesis and promote late-stage malignant progression (12) .
To determine if the cell of origin might influence the spectrum of lung tumors initiated in these mice, we used adenovirus vectors with lung cell-specific expression of Cre recombinase (14) . Ad-SPC-Cre, Ad-CCSP-Cre, and Ad-CGRP-Cre direct Cre expression to alveolar type II pneumocytes, Clara, or neuroendocrine cells, respectively. Of these, we noted that Ad-SPC-Cre was the most potent inducer of lung tumorigenesis in either BRaf CA or BRaf CA ; Pik3ca lat mice, and was equivalent in potency to Ad-CMV-Cre. Moreover, tumors emerging in mice initiated with either Ad-CCSP-Cre or Ad-CGRP-Cre, which were less potent in inducing lung tumorigenesis, displayed the cuboidal morphology and expression of SP-C characteristic of AT2 cells (data not shown).
In these experiments we assessed tumor grade at 22 weeks in groups of BRaf CA or BRaf CA ; Pik3ca lat mice initiated with Ad-SPC-Cre to confirm the ability of PIK3CA H1047R to promote malignant progression of BRAF V600E -initiated lung tumors ( Supplementary Fig. S4 ). As before, the majority of BRAF V600E -expressing lung tumors were small, grade 2 adenomas. In contrast, more than 50% of lung tumors in the BRaf CA ; Pik3ca lat mice were high-grade adenomas (grade 3) and 8.5% were either grade 4 adenosquamous cancers or adenocarcinomas, confirming observations made with Ad-CMV-Cre (36) .
TP53 constrains malignant progression of BRAF V600E / PIK3CA H1047R lung tumors
TP53 mutations frequently coexist with mutations in KRAS, BRAF, or PIK3CA mutations in human lung adenocarcinomas and TP53 mutation or silencing promotes malignant progression of either KRAS G12D -or BRAF V600E -driven lung tumors (6, 12) . Consequently, we determined if TP53 loss would enhance lung tumorigenesis initiated by the combined expression of BRAF V600E and PIK3CA H1047R . Tumorigenesis was initiated in a BRaf CA/CA ; Pik3ca lat , Trp53 lox/lox mouse with a BRaf CA ; Trp53 lox/lox mouse as a littermate control. Within 4 weeks, the former mouse displayed end-stage disease requiring euthanasia. Although the BRaf CA ; Trp53 lox/lox mouse had a tumor burden of 0.2% made up of mainly small hyperplasias with a solitary benign adenoma detected ( Supplementary Fig.  S5A ), the BRaf CA/CA ; Pik3ca lat , Trp53 lox/lox mouse had a tumor burden of 41% made up of high-grade, anaplastic adenocarcinoma. Moreover, these high-grade tumors stained positive for vimentin, a marker of epithelial-mesenchymal transition, lacked TTF-1/NKX2-1 expression, a marker of the distal lung epithelium, and displayed a high proliferative index (Ki67; Supplementary Fig. S5B ). Similar results were obtained using a second BRaf CA/þ ; Pik3ca lat , Trp53 lox/lox mouse.
PIK3CA H1047R promotes BRAF V600E -induced oncogenic transformation in vitro
An advantage of GEM models of cancer is the ability to engineer defined genetic alterations and then generate cell lines for in vitro analysis. To that end, we generated BRAF V600E / TP53 Null and BRAF V600E /PIK3CA H1047R /TP53 Null mouse lung cancer-derived cell lines (BT and BPT cells hereafter) from suitably manipulated mice (7) .
Because BT cells displayed a limited capacity for anchorageindependent growth, we engineered them to express either mCherry (control), PIK3CA H1047R or a myristoylated, constitutively activated AKT1 (M þ AKT1) to test whether activation of PI3K signaling might cooperate with BRAF V600E to influence the behavior of these cells (Fig. 6) . Cell extracts were analyzed by immunoblotting for the activation status of key nodes in the PI3K signaling pathway ( Fig. 6A ; Supplementary  Fig. S8A ). Compared with control, cells expressing either PIK3CA H1047R or MþAKT1 displayed elevated pPRAS40 and pRP-S6, whereas M þ AKT1-expressing cells displayed elevated levels of pAKT, p4E-BP1, pFOXO1, and pGSK3b. PIK3CA H1047R and M þ AKT1 cells also showed a decrease in p27 KIP1 expression. Consistent with the ability of PIK3CA H1047R to cooperate with BRAF V600E in lung tumorigenesis in vivo, expression of either PIK3CA H1047R or M þ AKT1 led to increased anchorageindependent colony formation in vitro (Fig. 6B) . Indeed, the parental and mCherry control BT lung cancer cells failed to form colonies in agarose even when cultured for approximately 8 weeks. In contrast, the PIK3CA H1047R or MþAKT1-expressing cells cloned with an efficiency of 1% and 1.4%, respectively, after 3 weeks. These data indicate that PI3K!AKT signaling cooperates with BRAF V600E in oncogenic transformation of cultured lung cancer cell lines.
The ability of BPT lung cancer cells to form colonies in agarose was assessed in the presence of various pathwaytargeted inhibitors. Unlike BT cells, BPT cells are capable of anchorage-independent colony formation (vehicle; Fig. 6C ). However, when cultured in the presence of an MEK inhibitor, a class 1 PI3K inhibitor, or an AKT inhibitor, colony formation was abolished even when cultured for 8 weeks (Fig. 6C; ref. 37 ). These data emphasize the ability of PI3K!AKT signaling to cooperate with BRAF V600E in promoting the transformed phenotype on lung cancer cells.
BRAF V600E /PIK3CA H1047R /TP53 Null lung cancer cell lines are sensitive to combined pharmacologic inhibition of RAF or PI3K pathway inhibition
To assess the mechanisms of cooperation between BRAF V600E and PIK3CA H1047R on the behavior of BPT cells, they were treated with various pathway-targeted inhibitors of BRAF V600E or PIK3CA H1047R signaling, either alone or in combination, at which time effects on cell viability or the celldivision cycle were assessed ( Fig. 7A-C) .
As expected, single-agent inhibition of MEK1/2 or class 1 PI3Ks effectively decreased cell proliferation. Moreover, the combination of these agents had the strongest antiproliferative Research.
on April 28, 2017. © 2013 American Association for Cancer cancerres.aacrjournals.org Downloaded from effects, showing at least an additive effect particularly in the mid-range of drug (Fig. 7A ). Despite its potency in vivo, singleagent AKT inhibition (MK-2206) was ineffective at preventing the growth of these cells (Fig. 7B ) even at 5 mmol/L. In addition, single-agent ERK1/2 inhibition (SCH772984) exerted a cytostatic effect, only decreasing cell viability at higher concentrations (>250 nmol/L; ref. 38 ). However, combined ERK1/2 plus AKT inhibition displayed cooperativity such that concentrations of inhibitors that had no single-agent effect had striking inhibitory effects on cell proliferation when combined (Fig. 7B) , which was further confirmed by Crystal Violet staining (Supplementary Fig. S6A) .
To assess the effects of the various agents on the cell-division cycle, BPT cells were incubated with the various agents either alone or in combination and then labeled with BrdUrd to assess S-phase progression ( Fig. 7C ; see Supplementary Table  S1 for drug concentrations). Vehicle-treated cells displayed a high proliferative index with more than 75% of cells incorporating BrdUrd. As expected, single-agent blockade of MEK1/2, ERK1/2, PI3K, or AKT led to decreased BrdUrd incorporation and increased the G 1 population with the PI3K inhibitor most potent, the MEK and ERK inhibitors roughly equipotent, and the AKT inhibitor least potent. Cells treated with combined MEK1/2 plus PI3K or ERK1/2 plus AKT inhibitors displayed the most profound effects on the cell-division cycle, in addition to displaying evidence of cell death as assessed by the number of nonadherent cells and cells with a sub-G 1 DNA content ( Fig. 7C and Supplementary Table S2 ). Taken together, these data indicate that BRAF V600E and PIK3CA H1047R cooperatively regulate the cell-division cycle and cell death in vitro.
BRAF V600E and PIK3CA H1047R likely regulate many biochemical processes in the cell to influence cell proliferation in vitro and tumorigenesis in vivo. To assess the molecular mechanisms of such oncogenic cooperation, we used RPPA analysis to quantify protein expression/modification in BPT cells treated with inhibitors ( Fig. 7D ). Triplicate cultures of BPT cells were treated with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), class 1 PI3Ks (GDC), or AKT1-3 (MK) either alone or in combination as indicated (Fig. 7D) . Before RPPA analysis, we confirmed that each of the agents had the anticipated biochemical effects ( Supplementary Fig. S6B ). As expected, inhibition of MEK1/2 or ERK1/2 led to strongly diminished pERK1/2 and promoted a modest increase in pAKT. Inhibition of PI3Ks or AKT led to strongly diminished pAKT with no obvious effects on pERK. Finally, the combinations of inhibitors potently suppressed both pERK1/2 and pAKT.
The triplicate samples were subject to RPPA analysis using antisera against more than 150 proteins or protein modifications (20, 21) . Unsupervised hierarchical clustering of the data indicated that samples clustered on the basis of the pathway inhibited such that MEKi-or ERKi-treated samples clustered together as did PI3Ki-and AKTi-treated samples ( Fig. 7D and Supplementary Fig. S7 ). Samples from cells treated with combined pathway inhibitors clustered separately from samples from cells treated with the various single agents with the ; TP53 null lung cancer-derived cells. A, BRAF V600E /TP53 null lung cancerderived cells were infected with retroviruses as described earlier. Cell extracts were analyzed by immunoblotting as indicated. Quantification of blots is included as Supplementary Fig. S8A . B, anchorage-independent growth of BRAF V600E /TP53 null lung cancer cells engineered to express mCherry, PIK3CA H1047R , or MþAKT1 was quantified over 3 weeks. C, BRAF V600E / PIK3CA H1047R /TP53 null lung cancer cells were plated in soft agar in the absence (vehicle) or presence of inhibitors of MEK1/2 (1 mmol/L PD325901), class 1 PI3K (5 mmol/L GDC-0941), or AKT (5 mmol/L MK-2206). Anchorageindependent growth was assessed over 3 weeks. RPPA analysis generated predictions with regard to the consequences of inhibition of BRAF V600E or PIK3CA H1047R signaling on regulators of cell proliferation, some of which were then validated in an independent sample set by immunoblotting ( Fig. 7E and Supplementary Fig. S8 ). As predicted by RPPA analysis, inhibition of MEK1/2!ERK1/2 signaling led to increased expression of the proapoptotic BCL-2 family protein BIM and decreased expression of c-MYC as well as cyclins D1 and A. In addition, inhibition of PIK3CA H1047R , but not AKT, promoted BIM expression and inhibited c-MYC and cyclins D1 and A, and led to elevated p27 KIP1 expression and suppression of pRP-S6. Consistent with the lack of the effect of MK-2206 against the proliferation of cultured BPT cell, we noted that inhibition of AKT had no single-agent effect on BIM, c-MYC, cyclins D1 or A, p4E-BP1 or pRP-S6, but largely extinguished phosphorylation of PRAS40, a known AKT substrate. Finally, combined inhibition of both MEK and PI3Ks displayed additive effects on expression of c-MYC, cyclins D1 and A and BIM, the latter correlating with increased cleaved caspases-3 (CC3) and -7 (CC7) that were also predicted by RPPA analysis. These analyses indicate the complexity with which these pathways cooperatively regulate apoptosis and the cell division cycle, which in turn influences tumor latency, burden, and malignant progression. Although these experiments do not identify a single mechanism of BRAF V600E -PIK3CA H1047R cooperation in lung carcinogenesis, they suggest numerous areas of future investigation.
Discussion
The mechanisms by which KRAS G12D promotes lung carcinogenesis in humans and mice remain incompletely understood. However, here we show that two well-credentialed KRAS.GTP effectors, BRAF and PIK3CA, cooperate to mimic the effects of oncogenic KRAS G12D in GEM models of lung cancer. Although BRAF V600E expression elicits benign lung tumorigenesis, such tumors rarely progress to lung cancer, which contrasts with KRAS G12D -initiated lung tumors (Fig. 7F) . Unexpectedly, we noted that PIK3CA H1047R failed to initiate lung tumorigenesis, even when combined with PTEN silencing, a result at odds with a previous report ( Fig. 7F; ref. 9 ). Indeed, no combination of heterozygous or homozygous Pik3ca lat and Pten lox initiated lung tumorigenesis, contrasting with the effects of a tetracycline-inducible PIK3CA H1047R transgene. It remains possible that strength of pathway activation, genetic background, or the promoter system may influence these disparate results, as suggested by similar observations in pancreatic cancer (31, 39) . However, the lack of PIK3CA H1047R effects in lung is consistent with the effects of PIK3CA H1047R in ovarian epithelial cells (10) . Furthermore, others have shown that PI3K activation through PTEN silencing failed to elicit lung tumorigenesis (22) . It is unclear whether the inability of PIK3CA H1047R to initiate lung tumorigenesis will be predictive of antitumor effects of pharmacologic inhibition targeting of PI3K in the clinic (9) .
Despite its inability to initiate tumorigenesis, PIK3CA H1047R cooperated with BRAF V600E in dramatic fashion to promote lethal lung tumorigenesis, which occurred with short latency and complete penetrance (Fig. 7F) . That PTEN silencing also cooperated with BRAF V600E , albeit less strikingly, confirmed these observations, indicating an important role for PI3-lipid signaling. Although at early time points, BRAF V600E /PIK3-CA H1047R -induced tumors were benign, 6 months postinitiation there was evidence of cancer progression in a manner reminiscent of KRAS G12D . Finally, TP53 silencing, in conjunction with combined BRAF V600E /PIK3CA H1047R expression, led to rapid lung cancer development, which showed signs of dedifferentiation and epithelial-to-mesenchymal transition, hallmarks of advanced disease (40) (41) (42) .
In conjunction with previous reports of the MEK1/2 and PI3K dependency of KRAS G12D -induced lung tumors (43) , the simplest explanation is that combined activation of RAF!MEK!ERK and PI3K!AKT signaling cooperates to accelerate benign tumorigenesis and to promote malignant lung cancer progression. Although activation of BRAF and PI3K signaling accounts for much of the phenotype associated with KRAS G12D expression, a role for other KRAS G12D effectors remains possible because approximately 10% of KRAS G12D -initiated tumors display malignant progression, whereas only approximately 3% to 8% of BRAF V600E /PIK3CA H1047R tumors do so (7) . Indeed, because approximately 10% or less of KRAS G12D -or BRAF V600E /PIK3CA H1047R -initiated lung tumors display malignant progression, there must be additional stochastic genetic/epigenetic changes in benign tumor cells that promote malignant progression as emphasized by the effects of TP53 silencing on the progression of KRAS G12D -or BRAF V600E / PIK3CA H1047R -initiated lung tumors.
The absence of malignant progression of BRAF V600E -initiated lung tumors has been ascribed to a senescence-like Figure 7 . Cooperative effects of combined pharmacologic blockade BRAF V600E and PIK3CA H1047R signaling on BRAF V600E /PIK3CA H1047R /TP53 null lung cancer-derived cells. A and B, BRAF V600E /PIK3CA H1047R /TP53 null lung cancer cells were treated with a range of concentrations of MEKi (PD325901), PI3Ki (GDC-0941), ERKi (SCH772984), or AKTi (MK-2206) either alone or in the indicated combinations for 72 hours when cell viability was measured using a CellTiter-Glo assay (Promega) and normalized to zero concentration values. C, BRAF V600E /PIK3CA H1047R /TP53 null lung cancer cells were treated with inhibitors of MEK1/2, ERK1/2, AKT1-3, or class 1 PI3Ks either alone or in the indicated combinations for 24 hours at concentrations listed in Supplementary  Table S1 . Cell-cycle status was assessed by FACS analysis of cells labeled with BrdUrd and propidium iodide. D, unsupervised clustering of RPPA analysis of cell extracts derived from cells treated in biologic triplicates with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), AKT1-3 (MK), or class 1 PI3Ks (GDC) either alone or in the indicated combinations for 24 hours. Full dataset is included as Supplementary Fig. S7 and an Excel file. E, cell extracts prepared from BPT lung cancer cells treated with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), AKT1-3 (MK), or class 1 PI3Ks (GDC) either alone or in the indicated combinations for 24 hours were analyzed by immunoblotting and quantified against b-actin ( Supplementary Fig. S8B ). F, mutationally activated KRAS G12D promotes lung hyperplasia (H), then benign adenomas (BA), some of which progress to NSCLCs. Similarly initiated expression of BRAF V600E leads to more rapid and numerous hyperplasia and benign adenomas but without progression to NSCLC, most likely due to a senescence-like growth arrest. Although PIK3CA H1047R fails to initiate pathology in the lung, when combined with BRAF V600E , it promotes rapid emergence of hyperplasias and benign adenomas, some of which progress to NSCLC. At the molecular level, BRAF V600E cooperates with PIK3CA H1047R to regulate the cell-division cycle and suppress apoptosis.
proliferative arrest, which is due to feedback inhibition of PI3lipid production (44) . This hypothesis is supported by our data because PIK3CA H1047R expression enhanced the proliferative capacity of BRAF V600E -initiated lung tumors. However, it remains unclear how PI3K signaling sustains the proliferation of these tumors. Previous data indicate cooperative regulation of cyclins and cyclin-dependent kinase inhibitor expression by these pathways (45) . Analysis of BPT cells suggests that the celldivision cycle is, indeed, under the coordinate control of both BRAF V600E and PIK3CA H1047R . However, future experiments are required to determine which of the nodes of cell-cycle regulation are essential to the observed cooperation.
BPT cells were sensitive to combined inhibition of BRAF V600E and PIK3CA H1047R with pathway-targeted agents. In general, single-agent inhibition of either pathway had inhibitory effects on the cell-division cycle without promoting apoptosis. In contrast, combined pathway inhibition had stronger inhibitory effects on the cell cycle and also promoted cell death in vitro and in vivo. That AKT inhibition was without effect against lung tumors initiated by BRAF V600E but potently suppressed the cooperation between BRAF V600E and PIK3CA H1047R suggests a genotype-drug response phenotype with regard to AKT inhibition in GEM models. Whether these data will translate into the clinical use of single or combined pathway-targeted interventions in humans with BRAF-mutated lung cancer remains an open question. Although KRAS mutation is frequent in lung cancer, expression of BRAF V600E or PIK3CA H1047R accounts for a smaller percentage of patients with NSCLC (2). Because mutated KRAS has proved to be an intractable pharmacologic target, it will be interesting to determine whether combined pathway-targeted inhibition of RAF and PI3K signaling will promote regression of KRASmutated lung cancers.
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